OncoC4

OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, founded in 2020, with subsidiaries in Nanjing, Guangzhou and Beijing, China, and Brisbane, Australia. The company discovers and develops novel biologics for the treatment of cancer, working across immune checkpoints including CTLA-4, CD24, PD-1/VEGF and the Siglec family, with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and CAR T-cell therapies. Its lead clinical candidate is gotistobart (BNT316/ONC-392), a next-generation anti-CTLA-4 antibody co-developed and commercialized with BioNTech under a strategic collaboration announced in March 2023. OncoC4 publishes no developer program, public API, SDK or developer documentation; its corporate website runs on the Umbraco CMS, which serves a default OpenID Connect / OAuth 2.0 discovery document and JWKS for CMS member authentication.

OncoC4 is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Life Sciences, and Oncology.

OncoC4’s developer surface includes authentication, product news, and 12 more developer resources.

🌐 Visit website 📡 Source on GitHub

16.0/100 emerging ▬ flat Agent 9/100 agent aware Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyBiopharmaceuticalLife SciencesOncologyImmunotherapyClinical TrialsHealthcarePharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 16.0/100 · emerging

Contract Quality 0.0 / 21

Developer Ergonomics 1.9 / 17

Commercial Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Governance 0.3 / 10

Discoverability 4.9 / 9

Regulatory Posture 7.1 / 15

Agent readiness — 9/100 · agent aware

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 10 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/oncoc4: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Scopes 1

OAuth scopes governing access to this provider's APIs.

Oncoc4 Scopes

OAuth 2.0 · no documented scopes

0 scopes

SCOPES

Resources

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Conformance

Conformance

Access & Security 3

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Authentication

Authentication

OAuthScopes

OAuthScopes

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 5

The organization behind the API

Website

About

Careers

News

LinkedIn

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: oncoc4
name: OncoC4
description: OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company headquartered in Rockville, Maryland,
  founded in 2020, with subsidiaries in Nanjing, Guangzhou and Beijing, China, and Brisbane, Australia. The company discovers
  and develops novel biologics for the treatment of cancer, working across immune checkpoints including CTLA-4, CD24, PD-1/VEGF
  and the Siglec family, with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and CAR T-cell therapies.
  Its lead clinical candidate is gotistobart (BNT316/ONC-392), a next-generation anti-CTLA-4 antibody co-developed and commercialized
  with BioNTech under a strategic collaboration announced in March 2023. OncoC4 publishes no developer program, public API,
  SDK or developer documentation; its corporate website runs on the Umbraco CMS, which serves a default OpenID Connect / OAuth
  2.0 discovery document and JWKS for CMS member authentication.
image: https://oncoc4.com/media/tlofbavh/logo.svg
url: https://raw.githubusercontent.com/api-evangelist/oncoc4/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Oncology
- Immunotherapy
- Clinical Trials
- Healthcare
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/oncoc4-domain-security.yml
- type: WellKnown
  url: well-known/oncoc4-well-known.yml
- type: Authentication
  url: authentication/oncoc4-authentication.yml
- type: OAuthScopes
  url: scopes/oncoc4-scopes.yml
- type: Conformance
  url: conformance/oncoc4-conformance.yml
- type: LLMsTxt
  url: llms/oncoc4-llms.txt
- type: Website
  url: https://oncoc4.com/en/
- type: About
  url: https://oncoc4.com/en/about-us/
- type: Contact
  url: https://oncoc4.com/en/contact/
- type: PrivacyPolicy
  url: https://oncoc4.com/en/privacy-policy/
- type: Careers
  url: https://oncoc4.com/en/careers/
- type: News
  url: https://oncoc4.com/en/news-resources/news/
- type: LinkedIn
  url: https://www.linkedin.com/company/oncoc4
- type: SecondaryMarket
  url: https://forgeglobal.com/oncoc4_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 9
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: OncoC4 is a late clinical-stage biopharmaceutical company whose product is a drug, not software — the entire oncoc4.com
    site is an Umbraco-hosted corporate brochure (about, pipeline, clinical trials, publications, careers) with no developer
    section, and the only machine-readable documents it serves are Umbraco's default OIDC/OAuth member-login discovery files.
  evidence:
  - url: https://oncoc4.com/openapi.json
    status: 404
  - url: https://oncoc4.com/api-docs
    status: 404
  - url: https://oncoc4.com/graphql
    status: 404
  - url: https://oncoc4.com/.well-known/agent-card.json
    status: 404
  - url: https://oncoc4.com/.well-known/openid-configuration
    status: 200
  checked: '2026-08-04'